Aviv Pudipeddi

The University of Sydney — Australia

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index297citations73works2.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(61), Microscopic Colitis(50), Liver Diseases and Immunity(11), Biosimilars and Bioanalytical Methods(11), Celiac Disease Research and Management(6)

Publications73 total

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn’s disease: rationale, design and protocol for the randomised controlled VECTORS trial
BMJ Open Gastroenterology·2026Open Access
P0981 Combination therapy with an immunomodulator improves persistence of anti-tumour necrosis factor agents but not vedolizumab or ustekinumab in Inflammatory Bowel Disease, with improved persistence seen with longer duration of initial combination therapy before de-escalation
Journal of Crohn s and Colitis·2026Open Access
P1162 Corticosteroid use during induction is associated with decreased persistence of advanced therapies in both Crohn’s Disease and Ulcerative Colitis
Journal of Crohn s and Colitis·2026Open Access
P1007 Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis
Journal of Crohn s and Colitis·2026
DOP086 Latitude Gradient in Advanced IBD Therapy Prescribing in Australia, 2007-2025
Journal of Crohn s and Colitis·2026
P0426 Cost savings and carbon footprint benefits of intestinal ultrasound versus colonoscopy for disease activity monitoring in Inflammatory Bowel Disease
Journal of Crohn s and Colitis·2026
P0898 Off-label upadacitinib 60mg daily in the rescue of refractory Ulcerative Colitis: An open labelled cohort study
Journal of Crohn s and Colitis·2026
P0599 Ustekinumab has the highest persistence in Crohn’s Disease, vedolizumab has the highest persistence in Ulcerative Colitis, and persistence declines from first- to fourth-line therapy
Journal of Crohn s and Colitis·2026
P1089 Corticosteroid use during maintenance is associated with decreased persistence of advanced therapies in Ulcerative Colitis but not in Crohn’s Disease
Journal of Crohn s and Colitis·2026
Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy
Therapeutic Advances in Gastroenterology·2026Open Access
P0603 Early tumour necrosis factor inhibitor initiation is associated with increased persistence in Crohn’s Disease but not Ulcerative Colitis, whereas early ustekinumab, vedolizumab and tofacitinib did not improve persistence
Journal of Crohn s and Colitis·2026
Interactions Between Sarcopenia, Physical Frailty and Resting Energy Expenditure in Cirrhosis and Portal Hypertension
Nutrients·2025Open Access
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia
Journal of Gastroenterology and Hepatology·2025Open Access
Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases
Therapeutic Advances in Gastroenterology·2025Open Access
Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC
Gastroenterology·2025· 2 cited
Tu1887: EARLY LYMPHOCYTOSIS IS A NOVEL PREDICTOR OF RESPONSE TO RESCUE INFLIXIMAB IN ACUTE SEVERE ULCERATIVE COLITIS: RESULTS FROM PREDICT-UC
Gastroenterology·2025
Su1943: CORRELATION OF BIOCHEMICAL, ENDOSCOPIC AND HISTOLOGIC ENDPOINTS IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL
Gastroenterology·2025
Su1907: EARLY FAECAL CALPROTECTIN PREDICTS CLINICAL OUTCOMES IN ACUTE SEVERE ULCERATIVE COLITIS: RESULTS FROM PREDICT-UC
Gastroenterology·2025
Su1899: EXTENSIVE DISEASE CLEARANCE AS A NOVEL COMPOSITE ENDPOINT TO PREDICT LONG-TERM RELAPSE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS: A POST-HOC ANALYSIS FROM THE VIEWS RANDOMISED CONTROLLED TRIAL
Gastroenterology·2025
1302: EARLY SERUM INFLIXIMAB LEVELS PREDICT CLINICAL OUTCOMES IN ACUTE SEVERE ULCERATIVE COLITIS: RESULTS FROM PREDICT-UC
Gastroenterology·2025
page 1 of 4Next →

Frequent Co-authors

Rupert W. Leong(38), Sudarshan Paramsothy(24), Miles Sparrow(15), Peter De Cruz(15), Viraj C. Kariyawasam(14), Lauren Beswick(14), Britt Christensen(12), C Li Wai Suen(11), Danny Con(11), Mayur Garg(11), Kristy Boyd(10), Ourania Rosella(10), David Proud(10), Richard Brouwer(10), Alexandra Gorelik(10), Danny Liew(10), Emily K. Wright(10), Michelle Sawers(10), Nik S. Ding(10), Matthew C. Choy(9)